Lilly stomach-cancer drug helps survival, study finds
Eli Lilly and Co. shares rose nearly 5 percent Monday morning after it said a study found that its experimental stomach-cancer drug helped patients with advanced disease live longer.
Eli Lilly and Co.
Articles
Lilly, Roche drugs chosen for Alzheimer’s prevention trial
Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
Lilly shares rise on Alzheimer’s study results
Eli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease, according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than 5 percent on the news.
Lilly counting on diabetes products to challenge larger rivals
Eli Lilly and Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.
State drug fraud cases on the rise, study says
Federal and state prosecutors have collected more than $30 billion from drug companies for alleged fraud and illegal marketing over the last 20 years, according to a new report by consumer advocacy group Public Citizen.
Group aims to cut costs of late-stage drugs
You know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help. But that’s exactly what happened last week when 10 major drug companies—including Eli Lilly and Co.—joined forces to cut costs out of clinical trials.
Lilly competitor Novo investing $100M in China
Novo Nordisk A/S, the world’s largest insulin maker, plans to spend $100 million on research in China. The move follows a similar one by Indianapolis-based Eli Lilly, which opened a 150-person research center in Shanghai in May.
Lilly’s Cialis gets European endorsement for new use
A European committee has endorsed the use of Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate.
Ten drugmakers team up to improve testing process
Pharmaceutical industry heavyweights, including Eli Lilly and Co., are teaming up to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.
FDA drug-review deal may unravel as fiscal cliff looms
A $6.4 billion accord for U.S. drug and medical-device reviews is set to unravel just three months after taking effect as lawmakers squabble over budget cutbacks.
Eli Lilly aims to ramp up social media presence
The drugmaker recently drafted social media guidelines it hopes can help it expand its use of social media to more of its employees—without running afoul of regulators.
Lilly’s Alimta fails to extend survival in lung cancer study
Eli Lilly and Co. said Thursday that its cancer drug Alimta didn’t extend overall survival when combined with Roche Holding AG’s Avastin in patients with a form of lung tumor.
Two more clinical trials go against Lilly
In the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company suffered two other setbacks with former stars of its pipeline.
Eli Lilly’s top lawyer to retire at end of year
Indianapolis-based drugmaker Eli Lilly and Co. said Thursday its general counsel, Robert Armitage, will retire at the end of the year and be replaced by deputy general counsel Michael Harrington.
Lilly stops testing of experimental schizophrenia drug
Eli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was unlikely to show a benefit in patients.
Lilly’s Alzheimer’s finding triggers investor hope, doctor caution
While investors supported the sliver of promise offered when Eli Lilly and Co. said its Alzheimer’s drug may slow progression early in the disease, doctors weren’t as impressed, saying it could take years to find out for sure.
Lilly wins appeal upholding patent for Alimta cancer drug
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
Alzheimer’s drug results leave Lilly ‘excited’ but uncertain
The surprise positive effect shown by an experimental Alzheimer’s drug “excited” executives at Eli Lilly and Co., but it raised as many questions as it answered.
Lilly’s Alzheimer’s drug trials show mixed results
Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.
Alzheimer’s quest puts Lilly to test
Odds are long that Eli Lilly and Co.’s leading Alzheimer’s drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.